SPYMAN #3

Cover shows notable wear including corner softening at top and bottom right, a vertical crease running through the upper right Comics Code box area, and general surface rubbing/scuffing across the cover. There is visible waviness/staining along the left edge and spine area suggesting handling and possible moisture exposure. Colors remain bright with no major color breaks, but edge wear and the crease keep this from a higher grade. Interior and back cover were not assessed.

Spyman was Harvey Comics' brief attempt to capitalize on the mid-1960s spy craze, launching in late 1966 with art contributed by Jim Steranko (credited as Jim Steranko, an early pseudonym period for Jim Steranko) and other Harvey-associated talent. The series ran only four issues before cancellation, making the entire run a scarce footnote in Silver Age publishing history rather than a sustained franchise. Issue #3, cover-dated February 1967, continues the title's blend of espionage adventure and superhero conventions that defined the brief series.

Market data for Spyman #3 is thin, reflecting the title's low print run and limited collector base relative to mainstream Marvel or DC output of the same era. Certified sales cluster in the near-mint range, with a 9.2 realizing $80 and a 9.0 at $60, while a 7.0 grade sold for $38, suggesting a fairly flat value curve across mid-to-high grades rather than the steep grade-sensitivity seen in more actively traded keys. The near-total absence of population and sales data above 9.6 points to genuine scarcity in top grades, though this scarcity has not yet translated into aggressive bidding given the book's narrow following.

Spyman #3 appeals primarily to Harvey Comics completists, Silver Age spy-genre collectors, and those assembling the full four-issue run rather than to speculative buyers chasing a recognized first appearance or landmark cover. Lower and mid-grade raw copies trade as affordable back-issue material with modest but steady demand, while a pristine certified copy would likely command a premium disproportionate to the book's modest sales history simply due to census scarcity at the top end. Overall, this is a book for patient specialists rather than broad-market speculation.